This site is intended only for healthcare professionals in UAE, Kuwait, Qatar, Bahrain, Oman.

Search

Menu

Close

Sign In or Register

Log Out Our Medicines Therapy AreasExplore ContentExplore Content

Events

Downloadable materialsVideos
Let's ConnectLet's ConnectContact usPfizer medical information

Sed volutpat ullamcorper enim, eget finibus lectus. Nunc in viverra velit, eu interdum ex. Pellentesque malesuada est ut est suscipit ultricies. Ut non nisl molestie, ullamcorper massa dignissim, sollicitudin quam. Aliquam pharetra dignissim turpis et laoreet. Ut tristique sollicitudin sagittis. Praesent ut ex non dolor mattis pulvinar vel sit amet ante. Ut molestie varius porta. Ut orci enim, consectetur quis euismod et, maximus at urna. Vestibulum sed libero at nulla maximus feugiat. Ut interdum iaculis porta. Nam feugiat eu sem non molestie. Maecenas convallis, justo laoreet tempus volutpat, risus ante euismod nulla, vel placerat ante purus vel orci. Sed volutpat ullamcorper enim, eget finibus lectus. Nunc in viverra velit, eu interdum ex. Pellentesque malesuada est ut est suscipit ultricies. Ut non nisl molestie, ullamcorper massa dignissim, sollicitudin quam. Aliquam pharetra dignissim turpis et laoreet. Ut tristique sollicitudin sagittis. Praesent ut ex non dolor mattis pulvinar vel sit amet ante. Ut molestie varius porta. Ut orci enim, consectetur quis euismod et, maximus at urna. Vestibulum sed libero at nulla maximus feugiat. Ut interdum iaculis porta. Nam feugiat eu sem non molestie. Maecenas convallis, justo laoreet tempus volutpat, risus ante euismod nulla, vel placerat ante purus vel orci.

Menu

Close

About About EMA-Approved RUXIENCE: the latest addition to Pfizer’s oncology portfolio Biosimilars: Highly similar versions of existing biologic medicines RUXIENCE was approved by the EMA based on the totality of evidence supporting high similarity to MabThera RUXIENCE is highly similar in structure and function to MabThera Similar PK profile to MabThera in subjects with active RA in a 3-ARM study EfficacySafetyDosing Support and Services EventsMaterials Videos

Information on how to access Ruxience® (Rituximab) prescribing information and adverse event reporting can be found at the bottom of the page.

Report Adverse Events 

If you'd like to report an adverse event related to a Pfizer Product from Gulf (UAE, Bahrain, Qatar, Oman and Kuwait), please send an email with the adverse event details to: [email protected]

Pfizerpro accountPfizerPro Account

Access Pfizer materials, resources and receive communications from Pfizer about our products with a Pfizerpro account.

Sign In or Register

AccountSign Out

Copyright © 2024 Pfizer Gulf FZ LLC. All rights reserved.

 

i- The product information provided in this site is intended only for Healthcare Professionals of UAE, Kuwait, Qatar, Bahrain, Oman.

 

ii- The information contained on this website is offered for educational purposes only and does not represent medical advice, diagnosis, treatment or a professional recommendation. Pfizer will not be responsible for the use or interpretation of the information by the user of the website.

 

iii- The products discussed herein may have a different product labeling than authorized in your country and may not be available in some territories.
 

PP-UNP-BHR-0298

You are now leaving Pfizer

You are now leaving Pfizerpro and will be directed to our provider to complete your registration. Any personal information that you may find pre-populated from your Pfizerpro profile, or you may provide, will be governed by our Privacy Policy. Your data will not be used for any other purpose.

 

You are now leaving PfizerPro
You are leaving the Pfizer Portal - would you like to continue?
 

​​​​​​​